Chairman. Global Director, Marketing and Business Development at ABIGO Medical AB. Previously business development and investment manager at GU Holding (now GU Ventures). Björn has 20+ years of international experience in senior marketing, sales, and business development roles within pharmaceuticals, medical devices, and biotech.
PhD. Björn has extensive experience from preclinical, early clinical, and external partnering activities in different positions within Biotech and Large Pharma R&D. He is currently the Business Development Director of Toleranzia, Sweden, which he previously managed as CEO. Positions previously held by Björn include: Head of Molecular Biology at Pharmacia, Director of Discovery Sciences AstraZeneca R&D, Head of Discovery Research Biovitrum, CSO of Arexis AB, and Director of External Collaborations at AstraZeneca R&D.
PhD. Co-founder of Alzinova. Full professor of molecular structural biology at the Swedish University of Agricultural Sciences (SLU) and Member of the Royal Swedish Academy of Science. Torleif brings 31 years of independent research experience and scientific expertise to the board, and is engaged as consultant for commercial drug development programs. He is also co-inventor of Alzinova’s AβCC peptide™ technology.
MD. Jan is since 1980 Professor of Medical Microbiology and Immunology at the University of Gothenburg, Sweden, as well as Director of the Göteborg University Research Institute (GUVAX). He has published more than 500 papers in the fields of microbiology, immunology and vaccinology, and is an elected member of the Swedish Royal Academy of Science, and the Swedish Royal Academy of Engineering. He has also served on many national and international boards, e.g. the Board of Directors of the Knut and Alice Wallenberg Foundation (Sweden), the International Vaccine Institute (IVI), and the Global Alliance for Vaccines and Immunization (GAVI). Holmberg is a member of several international vaccine-related technical task forces and steering committees.
MD. Clas is Chief Physician at the Department of Clinical Neuroscience, Sahlgrenska University Hospital in Gothenburg, Sweden. His specialty is Neurology and Clinical Immunology. Since 2001, Malmeström has been involved in Multiple Sclerosis (MS) research at the hospital’s own MS Centre. In addition to academic research, he has also been involved in several clinical trials within Multiple Sclerosis led by Biogen-Idec, Novartis, and Roche, of which several are now standard treatments.
PhD. Board alternate. Co-founder and CSO of Alzinova. Anders brings over 15 years of protein research to the board, with special emphasis on neurotoxic peptide aggregates for the last 8 years. He is also co-inventor of Alzinova’s AβCC peptide™ technology, and has been involved in its commercialization since 2008.